PROGRAMME N HOTEL SUISSE MAJESTIC - MONTREUX - OVEMBER 16 - 17, 2018 - SSIPM
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
10 th EDITION PROGRAMME NOVEMBER 16 – 17, 2018 HOTEL SUISSE MAJESTIC – MONTREUX www.ssipm.ch/fr/congres-annuel www.ssipm.ch/de/jahreskongress www.neuromodulation.ch
1
WELCOMING DRG THERAPY
to the Proclaim™ Neurostimulation Platform.
PREMIER THERAPY.* †
PREMIUM PLATFORM.
PRECISE** RELIEF.
The premier therapy for treating causalgia and CRPS of the lower
limbs on a premium platform for a better patient experience
LEARN MORE AT SJM.COM/PROCLAIMDRG
*When compared to traditional tonic spinal cord stimulation based on outcomes **Please note that in 1994, a consensus group of pain medicine experts gathered by the
from the ACCURATE IDE study. International Association for the Study of Pain (IASP) reviewed diagnostic criteria
**Precise pain in the foot, knee, hip or groin due to CRPS type I and II. and agreed to rename reflex sympathetic dystrophy (RSD) and causalgia, as complex
regional pain syndrome (CRPS) types I and II, respectively.
†Based on new technologies available for DRG therapy.
International: Management of chronic intractable pain.
SJM.com/ProclaimDRG
Contraindications: US: Patients who are unable to operate the system, who are
St. Jude Medical is now Abbott.
poor surgical risks, or who have failed to receive effective pain relief during trial
Rx Only stimulation. International: Patients who are unable to operate the system, are
Brief Summary: Prior to using these devices, please review the User’s Guide for a poor surgical risks, are pregnant, or under the age of 18. Warnings/Precautions:
complete listing of indications, contraindications, warnings, precautions, potential Diathermy therapy, implanted cardiac systems or other active implantable devices,
adverse events, and directions for use. The system is intended to be used with leads magnetic resonance imaging (MRI), computed tomography (CT), electrosurgery
and associated extensions that are compatible with the system. devices, ultrasonic scanning equipment, therapeutic radiation, explosive or
Indications for Use: flammable gases, theft detectors and metal screening devices, lead movement,
US: Spinal column stimulation via epidural and intra-spinal lead access to the operation of machinery and equipment, pediatric use, pregnancy, and case damage.
dorsal root ganglion as an aid in the management of moderate to severe chronic Adverse Effects: Painful stimulation, loss of pain relief, surgical risks
intractable* pain of the lower limbs in adult patients with Complex Regional Pain (e.g., paralysis). User’s Guide must be reviewed for detailed disclosure.
Syndrome (CRPS) types I and II.** CAUTION: FEDERAL LAW (USA) RESTRICTS THIS DEVICE TO SALE,
*Study subjects from the ACCURATE clinical study had failed to achieve adequate DISTRIBUTION AND USE BY OR ON THE ORDER OF A PHYSICIAN.
pain relief from at least 2 prior pharmacologic treatments from at least 2 different ™ Indicates a trademark of the Abbott group of companies.
drug classes and continued their pharmacologic therapy during the clinical study. © 2018 Abbott. All Rights Reserved.
29623-SJM-NANS-1117-0096c | Item approved for global use/A5.
3
CHANGING THE
CONVERSATION
WITH THE OPPORTUNITY
TO DELIVER MEANINGFUL
PATIENT OUTCOMES
SNAPSHOT™ REPORTING
DELIVERS OBJECTIVE
PATIENT DATA
TRANSFORM PATIENT CONVERSATIONS
FROM SUBJECTIVE TO OBJECTIVE.
COMPLEMENT SELF-REPORTING
WITH SHAREABLE ACTIVITY REPORTS
THAT VALIDATE PATIENT USAGE
AND TRACK THEIR PROGRESS.
www.medtronic.eu
UC201904914EN © 2018 Medtronic. All rights reserved.
5
6
7
8
9
EVERY PATIENT´S PAIN IS
DIFFERENT
HF10 SCS THERAPY IS
INDIVIDUALLY CUSTOMISED TO
EACH PATIENT´S NEEDS
TARGET OPTIMISATION
Customised electrode
combinations and amplitude
settings to optimise therapy
PULSE DOSING
Therapy cycles through a
specific on/off schedule
for precise durations
HF10
THERAPY
CUSTOMISATION
MAPS - MULTI-AREA
PAIN SEQUENCING
Combining different
programs to address new
and evolving pain
BIPOLE INTERLACING
Improving pain relief by
merging multiple bipole
programs into a single program
PARTNERING WITH YOU
AND YOUR PATIENTS TO
For more information visit
www.nevro.com
OPTIMISE PAIN RELIEF11
AKTIV
DURCHS
LEBEN
PALEXIA® RETARD
GEGEN CHRONISCHE
SCHMERZEN
retard
Palexia® retard (Tapentadol) I: Zur Behandlung von mittelstarken bis starken prolongierten Schmerzen bzw. bei ungenügender Wirksamkeit nicht-opioider Analgetika. D: Dosierung individuell dem Schweregrad der
zu behandelnden Schmerzen anpassen. Palexia® retard sollte zweimal täglich, ungefähr alle 12 Stunden eingenommen werden. Gesamtdosen von mehr als 500 mg Palexia® retard wurden nicht untersucht und werden
daher nicht empfohlen. KI: Überempfindlichkeit gegen Tapentadol oder einen sonstigen Bestandteil. Ausgeprägte Atemdepression, akutes oder starkes Bronchialasthma oder Hyperkapnie. Paralytischer Ileus. Akute
Intoxikation durch Alkohol, Schlafmittel, zentral wirksamen Analgetika oder psychotropen Substanzen. Nicht therapeutisch kontrollierte Epilepsie. VM: Bei der Anwendung potenter Opioide in der Schmerztherapie ist
die entsprechende medizinische Sorgfaltspflicht vorausgesetzt. IA: Die Einnahme von Palexia® ist bei gleichzeitiger Einnahme von MAO-Hemmern kontraindiziert. Bei gleichzeitiger Anwendung von Substanzen, die
ebenfalls auf das Zentralnervensystem wirken, ist mit einer gegenseitigen Verstärkung zu rechnen. UW: Übelkeit, Schwindel, Erbrechen, Somnolenz, Kopfschmerzen, Appetitverlust, Angst,
Verwirrtheit, Halluzinationen, Schlafstörungen, abnormale Träume, Tremor, Erröten, Obstipation, Diarrhö, Verdauungsstörungen, Mundtrockenheit, Juckreiz, vermehrtes Schwitzen, Hautau-
sschlag, Muskelspasmen, Erschöpfung, Müdigkeit, Gefühl der Körpertemperaturveränderung. P: Palexia® 25 mg, 50 mg, 100 mg, 150 mg, 200 mg und 250 mg à 30 und 60 Retardtabletten.
Kassenzulässig. Liste A+. Ausführliche Angaben siehe www.swissmedicinfo.ch. (01/2016) Grünenthal Pharma AG, 8756 Mitlödi, Tel. 055 647 31 31, www.palexia.ch13
15
Distributed by Parimed GmbH Unter Sagi 6, CH-6362 Stansstad Tel +41 (0)41 312 11 11 www.parimed.ch
17
!
10 9 8 7
1
18
6
2
3 4 519
INFINION™ CX 16 LEAD
Coverage Made Easy™
Simple Procedure – One Lead. One Needle. 16 Contacts
Seamless Coverage over three vertebral levels
Compatible With The Full Illumina 3D™ Portfolio
All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices
to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use
can be found in the product labeling supplied with each device. Information for the use only in countries with
applicable health authority registrations. Material not intended for use in France.
NM-492802-AA © 2017 Boston Scientific Corporation or its affiliates. All rights reserved. www.bostonscientific.euYou can also read
